Vial - lyophilised powderSubcutaneous (SQ)5 mg + 5 mg

This formulation pairs CJC 1295 without DAC with Ipamorelin. Both are researched for growth hormone release, but they act through different signals. The pairing is discussed in performance and recovery circles; its shorter acting rationale should not be mistaken for proof of improved sleep, muscle or recovery.

Shipping Information
Shipping Information

Free Shipping

Decor Outdoor offers free regular shipping on all orders shipped to residential or commercial addresses within the contiguous United States. Orders are delivered Monday through Friday (excluding holidays).

Drop Shipping

We are an online-only luxury furniture and lighting boutique, and do not have a warehouse. Consequently, all orders are drop shipped directly from our manufacturers to your door. If your order includes items from more than one manufacturer, you will receive multiple deliveries. Because we are dependent on the on-hand inventory of our manufacturing partners, some items listed on our site may not actually be available right away. Please call us at 888.784.4644 or via our contact form with any stocking questions and we'll get in touch with the appropriate manufacturer for answers, before you place your order.

Ground Shipping

Small parcel items ship regular ground via delivery services such as FedEx, UPS or DHL. Orders typically take 2-3 business days to process and in-stock items will usually be delivered 3-5 days from the date that they ship (depending on origin and destination). If there is a delay, you will be notified by email. No signature is required for standard ground shipping, so you may want to make arrangements to have packages brought inside soon after delivery, if you are unable to receive it in person.
Storage & Handling

Follow the storage instructions on your product label and the information supplied with your batch. Storage and handling requirements vary by product and presentation.

CJC 1295 without DAC and Ipamorelin are paired because they influence growth hormone release through different pathways. This version does not have the longer acting DAC component.

Where It Fits

Growth hormone signalling research and the study of combined approaches.

The PHI Perspective

Two ingredients need more explanation, not more promises. The rationale for a combination and the evidence for the finished formulation are different things.

For clinician-directed use only where permitted.

How It Works

One ingredient mimics the body's growth hormone releasing signal. The other acts on a different receptor linked to growth hormone release. Their combined effects need to be assessed directly.

What the Research Suggests

Both components have human pharmacology data, but the fixed combination itself has not been validated in controlled outcome trials. Any discussion of benefits should therefore stay anchored to mechanism and research context.

Evidence level: C. Component human data available; combination not trialled

Storage & Handling

Store lyophilised vial at 2-8 C, protected from light.

Active compound: CJC-1295 without DAC (Mod GRF 1-29) 5 mg + Ipamorelin 5 mg

Mechanism of Action

Dual-pathway stimulation of pituitary somatotrophs. CJC-1295 without DAC binds the GHRH receptor to increase pulse amplitude. Ipamorelin binds the growth hormone secretagogue receptor (GHS-R1a), amplifying release and reducing somatostatin inhibition. The two pathways are additive in preclinical work.

Clinical Evidence Base

Component-level evidence only. Ipamorelin reached Phase III for postoperative ileus and did not meet its primary endpoint. GHRH analogue pharmacology is well characterised. No controlled human trial of the combination for body composition, recovery or longevity endpoints has been published.

Safety & Precautions

Reported effects include injection-site reactions, transient flushing, headache, lightheadedness and increased appetite attributable to the ghrelin-receptor component. Fluid retention and arthralgia may occur with sustained GH elevation. Contraindicated where malignancy is present or suspected. IGF-1 monitoring is advised where use is continued.

Contraindications

Active or suspected malignancy; pregnancy and breastfeeding; proliferative diabetic retinopathy; acute critical illness; known hypersensitivity.

Literature & References

Raun K et al. Eur J Endocrinol, 1998 - ipamorelin, the first selective growth hormone secretagogue. | Beck DE et al. Am J Surg, 2014 - ipamorelin Phase III in postoperative ileus. | Teichman SL et al. J Clin Endocrinol Metab, 2006 - CJC-1295 endocrine effects.

Select the fields to be shown. Others will be hidden. Drag and drop to rearrange the order.
  • Image
  • SKU
  • Rating
  • Price
  • Stock
  • Availability
  • Add to cart
  • Description
  • Content
  • Weight
  • Dimensions
  • Additional information
Click outside to hide the comparison bar
Compare